The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

From the health benefits to side effects, here's what to know about the popular new GLP-1 weight loss medications.

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity epidemic, according to Reuters.

The Italian Medicines Agency is ready to evaluate the reimbursement of new drugs against obesity, following the British model ...

Obesity alters how medications work, increasing the risk of underdosing, overdosing, and unknown interactions. Are package ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...